Form 4: United Therapeutics Director Christopher Causey Reports Stock Transactions

Director Christopher Causey reported the acquisition and disposal of United Therapeutics Corp [UTHR] common stock on August 21, 2024.

Summary

• On August 21, 2024, Christopher Causey, a director of United Therapeutics Corp [UTHR], reported transactions involving the company's common stock.
• Causey acquired 1,210 shares of common stock at a price of $132.3 per share.
• Simultaneously, Causey disposed of 1,210 shares of common stock at a price of $349 per share.
• Following these transactions, Causey beneficially owns 4,185 shares of United Therapeutics Corp.
• Causey also exercised stock options for 1,210 shares at a price of $132.3.
• After the transaction, Causey owns 3,000 stock options.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by a company director. The sentiment is neutral as it doesn't inherently indicate positive or negative news about the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates